Press Release

PhRMA Statement on House Passage of PDUFA VI Reauthorization

PhRMA July 12, 2017

Washington, D.C. (July 12, 2017) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:

“Timely reauthorization of the Prescription Drug, Biosimilar and Generic Drug User Fee Acts is crucial to patients in need of life-saving treatments and enhancing the competitive market in biopharmaceutical innovation. The House took an important step in reauthorizing the user fee programs and we look forward to swift action in the Senate on behalf of America’s patients.”


About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:

www.PhRMA.org 
www.Innovation.org 
www.GoBoldly.com
www.Facebook.com/PhRMA 
www.Twitter.com/PhRMA